Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.

Yuya AonoNoriyuki EnomotoMasato KonoHidenori NakamuraKoshi YokomuraShiro ImokawaMikio ToyoshimaHideki YasuiHironao HozumiMasato KarayamaYuzo SuzukiKazuki FuruhashiTomoyuki FujisawaNaoki InuiTakafumi Suda

Published in: Therapeutic advances in respiratory disease (2021)

Concerning the FVC decline prior to and following antifibrotic therapy and a slow rate of FVC decline, only the FVC decline following the therapy is associated with a greater survival outcome. An early treatment decision may thus be beneficial for IPF.The reviews of this paper are available via the supplemental material section.

Keyphrases

idiopathic pulmonary fibrosis
interstitial lung disease
mesenchymal stem cells
bone marrow
systemic sclerosis
cell therapy
decision making